

John Y Kao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7773953/publications.pdf>

Version: 2024-02-01

94
papers

6,512
citations

87723

38
h-index

69108

77
g-index

99
all docs

99
docs citations

99
times ranked

10341
citing authors

#	ARTICLE	IF	CITATIONS
1	The gut microbiome in health and in disease. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 69-75.	1.0	1,193
2	Fecal Microbiota Transplant for Treatment of <i>Clostridium difficile</i> Infection in Immunocompromised Patients. <i>American Journal of Gastroenterology</i> , 2014, 109, 1065-1071.	0.2	546
3	<i>Helicobacter pylori</i> Immune Escape Is Mediated by Dendritic Cell-Induced Treg Skewing and Th17 Suppression in Mice. <i>Gastroenterology</i> , 2010, 138, 1046-1054.	0.6	279
4	<i>Candida albicans</i> and Bacterial Microbiota Interactions in the Cecum during Recolonization following Broad-Spectrum Antibiotic Therapy. <i>Infection and Immunity</i> , 2012, 80, 3371-3380.	1.0	230
5	Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats. <i>Gastroenterology</i> , 2014, 146, 484-496.e4.	0.6	212
6	Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 468-481.	2.3	189
7	Association between <i>Helicobacter pylori</i> infection and inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1077-1084.	0.9	187
8	Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 917-926.	0.9	176
9	High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for <i>Helicobacter pylori</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 895-905.e5.	2.4	158
10	The Role of Dendritic Cells in the Development of Acute Dextran Sulfate Sodium Colitis. <i>Journal of Immunology</i> , 2007, 179, 6255-6262.	0.4	151
11	Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent <i>Clostridium difficile</i> infection. <i>Anaerobe</i> , 2018, 53, 64-73.	1.0	144
12	Interleukin-22-mediated host glycosylation prevents <i>Clostridioides difficile</i> infection by modulating the metabolic activity of the gut microbiota. <i>Nature Medicine</i> , 2020, 26, 608-617.	15.2	136
13	Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. <i>Oncogene</i> , 2005, 24, 2354-2366.	2.6	131
14	Interplay between the Gastric Bacterial Microbiota and <i>Candida albicans</i> during Postantibiotic Recolonization and Gastritis. <i>Infection and Immunity</i> , 2012, 80, 150-158.	1.0	130
15	Dual biological effects of the cytokines interleukin-10 and interferon- γ . <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1529-1541.	2.0	129
16	Interleukin-10 Ablation Promotes Tumor Development, Growth, and Metastasis. <i>Cancer Research</i> , 2012, 72, 420-429.	0.4	129
17	Increased Expression of DUOX2 Is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine. <i>Gastroenterology</i> , 2015, 149, 1849-1859.	0.6	120
18	Tumor-Derived TGF- β Reduces the Efficacy of Dendritic Cell/Tumor Fusion Vaccine. <i>Journal of Immunology</i> , 2003, 170, 3806-3811.	0.4	118

#	ARTICLE	IF	CITATIONS
19	Association Between <i>Helicobacter pylori</i> and Barrett's Esophagus, Erosive Esophagitis, and Gastroesophageal Reflux Symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 239-245.	2.4	110
20	Intestinal dysbiosis in inflammatory bowel disease. <i>Gut Microbes</i> , 2011, 2, 211-216.	4.3	104
21	Butyrate increases IL-23 production by stimulated dendritic cells. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G1384-G1392.	1.6	102
22	Dietary l-serine confers a competitive fitness advantage to Enterobacteriaceae in the inflamed gut. <i>Nature Microbiology</i> , 2020, 5, 116-125.	5.9	93
23	<i>Helicobacter pylori</i> DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. <i>Gut</i> , 2011, 60, 1479-1486.	6.1	90
24	Treatment of <i>Helicobacter gastritis</i> with IL-4 requires somatostatin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12944-12949.	3.3	89
25	<i>Helicobacter pylori</i> -secreted factors inhibit dendritic cell IL-12 secretion: a mechanism of ineffective host defense. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G73-G81.	1.6	76
26	A Method for Cryogenic Preservation of Human Biopsy Specimens and Subsequent Organoid Culture. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 218-222.e7.	2.3	76
27	IL-10 produced by macrophages regulates epithelial integrity in the small intestine. <i>Scientific Reports</i> , 2019, 9, 1223.	1.6	72
28	Prior <i>Helicobacter pylori</i> infection ameliorates <i>Salmonella typhimurium</i> -induced colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1398-1408.	0.9	69
29	<i>Helicobacter pylori</i> eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. <i>Helicobacter</i> , 2018, 23, e12498.	1.6	66
30	Analysis of Germline GLI1 Variation Implicates Hedgehog Signalling in the Regulation of Intestinal Inflammatory Pathways. <i>PLoS Medicine</i> , 2008, 5, e239.	3.9	63
31	Gli1 Deletion Prevents <i>Helicobacter</i> -Induced Gastric Metaplasia and Expansion of Myeloid Cell Subsets. <i>PLoS ONE</i> , 2013, 8, e58935.	1.1	62
32	Tryptophan Catabolism Restricts IFN- γ -Expressing Neutrophils and <i>Clostridium difficile</i> Immunopathology. <i>Journal of Immunology</i> , 2014, 193, 807-816.	0.4	55
33	TLR2 Mediates <i>Helicobacter pylori</i> -Induced Tolerogenic Immune Response in Mice. <i>PLoS ONE</i> , 2013, 8, e74595.	1.1	47
34	Effects of Anti- <i>Helicobacter pylori</i> Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1991-1999.	2.4	46
35	<i>Helicobacter pylori</i> DNA's anti-inflammatory effect on experimental colitis. <i>Gut Microbes</i> , 2012, 3, 168-171.	4.3	41
36	Anti-Inflammatory Activity of Bone Morphogenetic Protein Signaling Pathways in Stomachs of Mice. <i>Gastroenterology</i> , 2014, 147, 396-406.e7.	0.6	41

#	ARTICLE	IF	CITATIONS
37	Expression of a Soluble TGF- β 2 Receptor by Tumor Cells Enhances Dendritic Cell/Tumor Fusion Vaccine Efficacy. <i>Journal of Immunology</i> , 2008, 181, 3690-3697.	0.4	39
38	Short-term and long-term impacts of <i>Helicobacter pylori</i> eradication with reverse hybrid therapy on the gut microbiota. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1968-1976.	1.4	39
39	Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. <i>Immunology Letters</i> , 2005, 101, 154-159.	1.1	38
40	CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor γ in Active Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 905-915.	0.6	38
41	<i>Helicobacter pylori</i> directs tolerogenic programming of dendritic cells. <i>Gut Microbes</i> , 2010, 1, 325-329.	4.3	37
42	Effective Colorectal Cancer Education for Asian Americans: A Michigan Program. <i>Journal of Cancer Education</i> , 2010, 25, 146-152.	0.6	35
43	DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
44	Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of <i>Helicobacter pylori</i> Infection in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1427-1433.	2.4	32
45	Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1821-1833.	2.8	30
46	Dual NADPH oxidases DUOX1 and DUOX2 synthesize NAADP and are necessary for Ca ²⁺ signaling during T cell activation. <i>Science Signaling</i> , 2021, 14, eabe3800.	1.6	28
47	Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity. <i>Gastroenterology</i> , 2018, 154, 140-153.e17.	0.6	27
48	Outcomes of furazolidone- and amoxicillin-based quadruple therapy for <i>Helicobacter pylori</i> infection and predictors of failed eradication. <i>World Journal of Gastroenterology</i> , 2018, 24, 4596-4605.	1.4	26
49	Aim2-mediated/IFN- β -independent regulation of gastric metaplastic lesions via CD8+ T cells. <i>JCI Insight</i> , 2020, 5, .	2.3	26
50	Eosinophilic esophagitis: update on management and controversies. <i>BMJ: British Medical Journal</i> , 2017, 359, j4482.	2.4	25
51	Chemotaxis Allows Bacteria To Overcome Host-Generated Reactive Oxygen Species That Constrain Gland Colonization. <i>Infection and Immunity</i> , 2018, 86, .	1.0	24
52	<i>Helicobacter pylori</i> Outer Membrane Protein 18 (Hp1125) Induces Dendritic Cell Maturation and Function. <i>Helicobacter</i> , 2005, 10, 424-432.	1.6	23
53	Catechins and Sialic Acid Attenuate <i>Helicobacter pylori</i> -Triggered Epithelial Caspase-1 Activity and Eradicate <i>Helicobacter pylori</i> Infection. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-13.	0.5	23
54	Somatostatin inhibits dendritic cell responsiveness to <i>Helicobacter pylori</i> . <i>Regulatory Peptides</i> , 2006, 134, 23-29.	1.9	22

#	ARTICLE	IF	CITATIONS
55	Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience. Digestive Diseases and Sciences, 2018, 63, 437-445.	1.1	22
56	How Can Individuals and the GI Community Reduce Climate Change?. Gastroenterology, 2020, 158, 14-17.	0.6	19
57	Increased risk for inflammatory bowel disease in congenital hypothyroidism supports the existence of a shared susceptibility factor. Scientific Reports, 2018, 8, 10158.	1.6	17
58	Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of <i>Helicobacter pylori</i> infection. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1731-1737.	1.4	17
59	<i>Helicobacter pylori</i> -Pulsed Dendritic Cells Induce <i>H. pylori</i> -Specific Immunity in Mice. Helicobacter, 2008, 13, 200-208.	1.6	16
60	IRAK-M modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells. Immunology Letters, 2012, 144, 49-59.	1.1	16
61	Early timing of single balloon enteroscopy is associated with increased diagnostic yield in patients with overt small bowel bleeding. Journal of the Formosan Medical Association, 2019, 118, 1644-1651.	0.8	14
62	Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection. Microbiology Spectrum, 2022, 10, .	1.2	14
63	Detection of colonic inflammation with Fourier transform infrared spectroscopy using a flexible silver halide fiber. Biomedical Optics Express, 2010, 1, 1014.	1.5	13
64	Distinct Physiological Characteristics of Isolated Laryngopharyngeal Reflux Symptoms. Clinical Gastroenterology and Hepatology, 2020, 18, 1466-1474.e4.	2.4	13
65	A Little O ₂ May Go a Long Way in Structuring the GI Microbiome. Gastroenterology, 2014, 147, 956-959.	0.6	12
66	Dendritic cell-derived TGF β 2 mediates the induction of mucosal regulatory T cell response to <i>Helicobacter</i> infection essential for maintenance of immune tolerance in mice. Helicobacter, 2020, 25, e12763.	1.6	12
67	<i>Helicobacter pylori</i> : beneficial for most?. Expert Review of Gastroenterology and Hepatology, 2011, 5, 649-651.	1.4	11
68	The effect of CT26 tumor-derived TGF β 2 on the balance of tumor growth and immunity. Immunology Letters, 2017, 191, 47-54.	1.1	11
69	Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of <i>Helicobacter pylori</i> infection. Helicobacter, 2021, 26, e12840.	1.6	11
70	Use of a donor heart with symptomatic WPW in an alternate donor program. Journal of Heart and Lung Transplantation, 2002, 21, 1310-1313.	0.3	10
71	Role of Dietary Metabolites in Regulating the Host Immune Response in Gastrointestinal Disease. Frontiers in Immunology, 2017, 8, 51.	2.2	9
72	Packaging and Waste in the Endoscopy Suite. Techniques and Innovations in Gastrointestinal Endoscopy, 2021, 23, 371-375.	0.4	9

#	ARTICLE	IF	CITATIONS
73	Does stress induce bowel dysfunction?. Expert Review of Gastroenterology and Hepatology, 2014, 8, 583-585.	1.4	8
74	Reverse Microbiomics: A New Reverse Dysbiosis Analysis Strategy and Its Usage in Prediction of Autoantigens and Virulent Factors in Dysbiotic Gut Microbiomes From Rheumatoid Arthritis Patients. Frontiers in Microbiology, 2021, 12, 633732.	1.5	8
75	<sc>CCR</sc>2 mediates <i>Helicobacter pylori</i>-induced immune tolerance and contributes to mucosal homeostasis. Helicobacter, 2017, 22, e12366.	1.6	6
76	Regional Control of Regulatory Immune Cells in the Intestine. Current Pathobiology Reports, 2018, 6, 29-34.	1.6	6
77	Aberrant T helper cell response in tumor-bearing mice limits the efficacy of dendritic cell vaccine. Immunology Letters, 2006, 105, 16-25.	1.1	5
78	Anaplastic Lymphoma Masquerading as Sclerosing Mesenteritis: A Case Report. Journal of Gastrointestinal Cancer, 2012, 43, 364-366.	0.6	5
79	Recent advances in pediatric celiac disease. Expert Review of Gastroenterology and Hepatology, 2017, 11, 583-592.	1.4	5
80	Considering Global Vaccination against Helicobacter pylori. Southern Medical Journal, 2010, 103, 185-186.	0.3	5
81	Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies. BioMed Research International, 2014, 2014, 1-4.	0.9	4
82	594 EFFICACY OF HIGH-DOSE DUAL THERAPY AND BISMUTH QUADRUPLE THERAPY IN FIRST-LINE AND RESCUE HELICOBACTER PYLORI ERADICATION – A FINAL REPORT OF MULTI-CENTER, RANDOMIZED CONTROL STUDY. Gastroenterology, 2021, 160, S-115.	0.6	2
83	Regional control of regulatory immune cells in the intestine. Current Pathobiology Reports, 2018, 6, 29-34.	1.6	2
84	316 Genotypic Testing Is Suboptimal to Predict Antibiotic Resistance and Therapeutic Outcome for Helicobacter pylori Eradication in Clinical Practice. Gastroenterology, 2016, 150, S73.	0.6	1
85	A report of nonexistence of the non-Helicobacter pylori Helicobacter species in Iranian patients suffering from inflammatory bowel disease. Folia Microbiologica, 2021, 66, 751-759.	1.1	1
86	Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus. PLoS ONE, 2022, 17, e0265323.	1.1	1
87	Contributions From Gastroenterology: Acid Peptic Disorders, Barrett's Esophagus and Eosinophilic Esophagitis. Gastroenterology, 2018, 154, 1209-1214.	0.6	0
88	Time to Make a Change in the Cutoff Value of Clarithromycin Resistance in the Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 2018, 113, 142-143.	0.2	0
89	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1647-1648.	2.4	0
90	2403. Clostridium difficile ribotypes and human microbiota differ in Taiwan and the United States with respect to diarrheal patients. Open Forum Infectious Diseases, 2019, 6, S829-S830.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Reply. <i>Gastroenterology</i> , 2020, 159, 799.	0.6	0
92	Book report. <i>Gut Microbes</i> , 2020, 11, 632-632.	4.3	0
93	792. Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, S439-S440.	0.4	0
94	Treatment considerations in <i>Helicobacter pylori</i> management. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, S22-S28.	1.9	0